

EY Pharma Agentic AI – Innovation Brief for Tiotropium

Region: India | Time Horizon: 5 years | User Query: Whats its cost


Executive Summary

Synthesizing findings for Tiotropium in India over 5 years. Strategic Signals

- Whitespace: High-value but under-explored market: estimated market size ~USD 155m with only 2 active/recruiting trials in the mock pipeline.
- Opportunity: Key patent US1234567A (composition) expires in 2025, suggesting a window for biosimilars or differentiated formulations. Agent Findings
- IQVIA Insights Agent: Market for Tiotropium in India grew from USD 120m in 2021 to 155m in 2024, with a CAGR of ~7.9%. Competition is moderate with 4 active players.
- EXIM Trade Agent: In India, latest mock EXIM data shows imports of 620 kg and exports of 70 kg for Tiotropium, at an average unit price of USD 115. Key source countries: China|Germany.
- Patent Landscape Agent: Mock patent landscape shows 3 filings for Tiotropium. Earliest expiry is US1234567A (composition) expiring in 2025 with FTO risk rated 'high'.
- Clinical Trials Agent: Mock clinical pipeline in India shows 2 active or recruiting trials for Tiotropium, across phases: {'Phase 3': 1, 'Phase 2': 1}.
- Web Intelligence Agent: Mock web and guideline snippets indicate persistent symptoms and poor inhaler technique in COPD patients on tiotropium, and underutilisation in severe asthma despite evidence of benefit.

IQVIA Insights Agent


Market for Tiotropium in India grew from USD 120m in 2021 to 155m in 2024, with a CAGR of ~7.9%. Competition is moderate with 4 active players.



therapy_area	country	year	molecule	market_size_usd_mn	cagr_pct	competitors
Respiratory	India	2021	Tiotropium	120	8.5	3
Respiratory	India	2024	Tiotropium	155	7.9	4

EXIM Trade Agent

In India, latest mock EXIM data shows imports of 620 kg and exports of 70 kg for Tiotropium, at an average unit price of USD 115. Key source countries: China|Germany.



molecule	country	year	import_volume_kg	export_volume_kg	unit_price_usd	top_source_countries
Tiotropium	India	2021	500	50	120	China Germany
Tiotropium	India	2024	620	70	115	China Germany


Patent Landscape Agent

Mock patent landscape shows 3 filings for Tiotropium. Earliest expiry is US1234567A (composition) expiring in 2025 with FTO risk rated 'high'.

molecule	patent_no	assignee	patent_type	indication	filing_year	expiry_year	status	fto_risk
Tiotropium	US1234567A	BigPharma A	composition	COPD	2005	2025	granted	high
Tiotropium	US2345678B	BigPharma B	device + formulation	Asthma	2012	2032	granted	medium
Tiotropium	IN3456789C	Generics Co	process	COPD	2018	2038	pending	low

Clinical Trials Agent

Mock clinical pipeline in India shows 2 active or recruiting trials for Tiotropium, across phases: {'Phase 3': 1, 'Phase 2': 1}.



nct_id	molecule	indication	phase	status	sponsor	country	start_year	estimated_completion_year
NCT00000001	Tiotropium	COPD	Phase 3	Active	BigPharma A	India	2022	2026
NCT00000002	Tiotropium	Asthma	Phase 2	Recruiting	Academic B	India	2023	2027

Web Intelligence Agent

Mock web and guideline snippets indicate persistent symptoms and poor inhaler technique in COPD patients on tiotropium, and underutilisation in severe asthma despite evidence of benefit.